^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    OSE-279

    i
    Other names: OSE-279, OSE 279, OSE279
    Associations

    News

    Trials
    Company:
    OSE Immunotherapeutics
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    14d
    A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours. (PubMed, Eur J Cancer)
    OSE-279 monotherapy was well tolerated with durable responses in patients with advanced solid tumours. The trial is continuing with OSE-279 combined with OSE2101, a therapeutic cancer vaccine in 1st line HLA-A2 positive PD-L1 ≥ 50% NSCLC. CLINICAL TRIAL REGISTRATION (NCT NUMBER: NCT05751798).
    P1 data • PK/PD data • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HLA-A*02 positive
    |
    Tedopi (OSE 2101) • OSE-279
    8ms
    Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
    P1/2, N=41, Recruiting, OSE Immunotherapeutics | N=24 --> 41
    Enrollment change
    |
    MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    Tedopi (OSE 2101) • OSE-279
    10ms
    Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
    P1/2, N=24, Recruiting, OSE Immunotherapeutics | Trial completion date: Dec 2024 --> Dec 2029 | Trial primary completion date: Oct 2024 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    OSE-279
    almost2years
    Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
    P1/2, N=24, Recruiting, OSE Immunotherapeutics | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: May 2024 --> Oct 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    MSI (Microsatellite instability)
    |
    OSE-279
    3years
    Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
    P1/2, N=24, Recruiting, OSE Immunotherapeutics
    New P1/2 trial • Metastases
    |
    MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    OSE-279